NO784397L - Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater

Info

Publication number
NO784397L
NO784397L NO784397A NO784397A NO784397L NO 784397 L NO784397 L NO 784397L NO 784397 A NO784397 A NO 784397A NO 784397 A NO784397 A NO 784397A NO 784397 L NO784397 L NO 784397L
Authority
NO
Norway
Prior art keywords
phtalazin
preparation
acid derivatives
therapeutically active
actic acid
Prior art date
Application number
NO784397A
Other languages
English (en)
Other versions
NO154346B (no
NO154346C (no
Inventor
David Robert Brittain
Robin Wood
Original Assignee
Ici Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Ltd filed Critical Ici Ltd
Publication of NO784397L publication Critical patent/NO784397L/no
Publication of NO154346B publication Critical patent/NO154346B/no
Publication of NO154346C publication Critical patent/NO154346C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO784397A 1977-12-29 1978-12-28 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater. NO154346C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5414277 1977-12-29

Publications (3)

Publication Number Publication Date
NO784397L true NO784397L (no) 1979-07-02
NO154346B NO154346B (no) 1986-05-26
NO154346C NO154346C (no) 1986-09-03

Family

ID=10470067

Family Applications (1)

Application Number Title Priority Date Filing Date
NO784397A NO154346C (no) 1977-12-29 1978-12-28 Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater.

Country Status (31)

Country Link
US (2) US4251528A (no)
EP (1) EP0002895B1 (no)
JP (2) JPS5495582A (no)
AT (1) AT365581B (no)
AU (1) AU516264B2 (no)
BG (1) BG34336A3 (no)
CA (1) CA1107732A (no)
CS (1) CS241015B2 (no)
CY (1) CY1219A (no)
DD (1) DD141021A5 (no)
DE (1) DE2861170D1 (no)
DK (1) DK151253C (no)
ES (1) ES476496A1 (no)
FI (1) FI64357C (no)
GR (1) GR65303B (no)
HK (1) HK22484A (no)
HU (1) HU182585B (no)
IE (1) IE47592B1 (no)
IL (1) IL56099A0 (no)
IN (1) IN150196B (no)
IT (1) IT1110885B (no)
MY (1) MY8500359A (no)
NO (1) NO154346C (no)
NZ (1) NZ189034A (no)
PH (1) PH15435A (no)
PL (1) PL118443B1 (no)
PT (1) PT68956A (no)
SG (1) SG68683G (no)
SU (3) SU1087075A3 (no)
YU (3) YU41607B (no)
ZW (1) ZW24978A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
CA1143733A (en) * 1979-07-31 1983-03-29 Masao Yoshida Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
WO1993013092A1 (en) * 1986-11-24 1993-07-08 Reinhard Sarges Imidazolidinedione derivatives
GB8704569D0 (en) * 1987-02-26 1987-04-01 Ici America Inc Therapeutic agent
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
DK607188A (da) * 1987-11-02 1989-06-22 Merck & Co Inc Tablet indeholdende en phthalazineddikesyreforbindelse
EP0315249A1 (en) * 1987-11-02 1989-05-10 Merck & Co. Inc. Phthalazineacetic acid composition and tablet
US4880928A (en) * 1987-12-21 1989-11-14 Merck & Co., Inc. Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4940791A (en) * 1988-02-29 1990-07-10 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
EP0397930A1 (en) * 1989-05-18 1990-11-22 Merck & Co. Inc. Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308A0 (fi) * 1989-12-15 1992-05-21 Pfizer Substituerade oxoftalazinylaettiks- syror och deras analoger.
US5037831A (en) * 1990-05-21 1991-08-06 American Home Products Corporation Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors
FR2682108B1 (fr) * 1991-10-07 1994-01-07 Lipha Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant.
CA2145640C (en) * 1992-09-28 2001-01-30 Banavara L. Mylari Substituted pyrimidines for control of diabetic complications
US5668279A (en) * 1992-11-02 1997-09-16 Merck & Co., Inc. Substituted phthalazinones as neurotensin antagonists
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
WO1995003053A1 (en) * 1993-07-26 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. Oxophthalazines for treating cachexia
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
AU6473898A (en) * 1997-03-21 1998-10-20 Regents Of The University Of California, The Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
EA002885B1 (ru) * 1997-04-15 2002-10-31 Ссир Средства растительного происхождения для подавления аппетита
SK7522001A3 (en) * 1998-03-31 2002-02-05 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
AP2001002359A0 (en) * 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
EP1236720B1 (en) 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
MXPA03008850A (es) 2001-03-30 2003-12-04 Pfizer Prod Inc Inhibidores de aldosa reductasa del grupo de las piridazinonas.
PL367112A1 (en) * 2001-04-30 2005-02-21 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
AU761191B2 (en) 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
WO2003092696A1 (en) * 2002-04-30 2003-11-13 Novartis Ag Method for decreasing capillary permeability in the retina
JP2006500336A (ja) * 2002-07-26 2006-01-05 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 糖尿病合併症の処置に使用するための置換インドールアルカン酸誘導体及びそれを含む製剤。
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
JP4838582B2 (ja) * 2004-12-27 2011-12-14 岐阜プラスチック工業株式会社 台車用本体
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
EP2139330B1 (en) 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
US8785483B2 (en) 2010-12-23 2014-07-22 The Board Of Regents Of The University Of Texas System Methods for treating COPD
EP2931280B1 (en) * 2012-12-14 2018-02-14 Phusis Therapeutics Inc. Methods and compositions for inhibiting cnksr1
CA2983260C (en) 2015-04-20 2024-01-23 Phusis Therapeutics, Inc. Sulfonamide compounds, compositions and methods for inhibiting cnksr1
US12090142B2 (en) 2018-02-22 2024-09-17 Board Of Regents, The University Of Texas System Combination therapy for the treatment of cancer
EP3862160A4 (en) * 2018-10-04 2022-08-10 Nitto Denko Corporation HEAT RESISTANT RELEASE FILM AND THERMAL COMPRESSION BONDING PROCESS
JP6751974B1 (ja) * 2019-10-16 2020-09-09 株式会社コバヤシ 離型フィルム及び離型フィルムの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833579A (en) * 1935-11-11 1974-09-03 Inoue Michiro 4-carbamoyl phthalazones
JPS5116430B2 (no) * 1971-08-05 1976-05-24
GB1398549A (en) * 1972-11-06 1975-06-25 Boots Co Ltd Phthalazine derivatives and their use in pharmaceutical compo sitions
AR205004A1 (es) * 1973-10-30 1976-03-31 Ishikawa M Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona
DE2451117A1 (de) * 1973-10-31 1975-05-22 Boots Co Ltd Therapeutisch wirksame verbindungen
GB1502312A (en) 1975-03-20 1978-03-01 Ici Ltd Quinolone derivatives
IE43079B1 (en) * 1975-03-20 1980-12-17 Ici Ltd Quinolone derivatives
JPS5214788A (en) * 1975-07-21 1977-02-03 Fuji Photo Film Co Ltd Process for preparing phthalazinone and its derivatives
NL7702763A (nl) * 1976-03-18 1977-09-20 Takio Shimamoto En Masayuki Is Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten.
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4293553A (en) * 1978-08-11 1981-10-06 Masayuki Ishikawa 1-Phthalazone derivatives, and use thereof

Also Published As

Publication number Publication date
YU312778A (en) 1983-01-21
GR65303B (en) 1980-08-01
PH15435A (en) 1983-01-18
IL56099A0 (en) 1979-01-31
YU42807B (en) 1988-12-31
ZW24978A1 (en) 1980-10-22
IE47592B1 (en) 1984-05-02
MY8500359A (en) 1985-12-31
JPS5495582A (en) 1979-07-28
IT1110885B (it) 1986-01-06
SU1087075A3 (ru) 1984-04-15
PT68956A (en) 1979-01-01
DK151253C (da) 1988-05-16
FI64357B (fi) 1983-07-29
JPS6326110B2 (no) 1988-05-27
ATA937678A (de) 1981-06-15
FI64357C (fi) 1983-11-10
BG34336A3 (bg) 1983-08-15
YU232082A (en) 1983-01-21
YU232182A (en) 1983-01-21
YU42054B (en) 1988-04-30
EP0002895B1 (en) 1981-10-14
NO154346B (no) 1986-05-26
FI783844A7 (fi) 1979-06-30
SG68683G (en) 1984-08-03
US4251528A (en) 1981-02-17
SU1272984A3 (ru) 1986-11-23
US4393062A (en) 1983-07-12
HU182585B (en) 1984-02-28
AU4204078A (en) 1979-07-05
IE782337L (en) 1979-06-29
JPS63119469A (ja) 1988-05-24
IN150196B (no) 1982-08-14
IT7852480A0 (it) 1978-12-28
CA1107732A (en) 1981-08-25
JPH0262532B2 (no) 1990-12-26
PL118443B1 (en) 1981-10-31
AU516264B2 (en) 1981-05-28
SU1072803A3 (ru) 1984-02-07
CY1219A (en) 1984-04-06
NZ189034A (en) 1981-11-19
YU41607B (en) 1987-12-31
EP0002895A1 (en) 1979-07-11
DK151253B (da) 1987-11-16
CS241015B2 (en) 1986-03-13
AT365581B (de) 1982-01-25
NO154346C (no) 1986-09-03
DK541878A (da) 1979-06-30
HK22484A (en) 1984-03-23
ES476496A1 (es) 1979-04-16
DD141021A5 (de) 1980-04-09
DE2861170D1 (en) 1981-12-24

Similar Documents

Publication Publication Date Title
NO784397L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ftalazin-4-yl-eddiksyrederivater
NO784211L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive acylanilid-derivater
NO784231L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive benzotiazinderivater
NO773384L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1-aryloksy-2-hydroksy-3-alkylenaminopropan-derivater
NO148148C (no) Fremgangsmaate til fremstilling av terapeutisk aktive 4-hydroksy-2-pyrrolidinonderivater
NO151966C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme imidazol-5-eddiksyrederivater
NO155055C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-carboxylsyrederivater.
SE431088B (sv) Forfarande for framstellning av terapeutiskt verksamma benshydrylsulfinylderivat
NO803136L (no) Fremgangsmaate for fremstilling av farmakologisk aktive 6beta-hydroksyalkylpenicillansyrederivater
NO780883L (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive 4-acylamino-fenyl-etanolaminer
NO151201C (no) Fremgangsmaate for fremstilling av terapeutisk virksomme antigenderivater
NO781880L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzodiazepinderivater
NO146865C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 16-dehydro-androstanderivater
NO782756L (no) Fremgangsmaate for fremstilling av terapeutisk aktive antrakinonderivater
NO151288C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolokinolizindiner
NO792139L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazoloksamsyre-derivater
NO152005C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karboksylsyrederivater
NO150605C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinyl-aminoalkyletere
NO834363L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sesquiterpenderivater
NO781878L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner.
NO781879L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridobenzodiazepiner
NO780214L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive aminoalkoksyfenylderivater
NO790394L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkanolaminderivater
NO790523L (no) Analogifremgangsmaate for fremstilling av farmasoeytisk aktive 2-fenyliminoimidazolidiner
NO772329L (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive imidazolinderivater